<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2221-2434</journal-id>
<journal-title><![CDATA[Revista Finlay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Finlay]]></abbrev-journal-title>
<issn>2221-2434</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Cienfuegos. Centro Provincial de información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2221-24342022000400417</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Polifarmacia en pacientes con diabetes tipo 2 e hipertensión arterial atendidos en un hospital provincial]]></article-title>
<article-title xml:lang="en"><![CDATA[Polypharmacy in Patients with Type 2 Diabetes and Arterial Hypertension Treated in a Provincial Hospital]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Asenjo Alarcón]]></surname>
<given-names><![CDATA[José Ander]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Autónoma de Chota  ]]></institution>
<addr-line><![CDATA[Cajamarca ]]></addr-line>
<country>Peru</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>12</volume>
<numero>4</numero>
<fpage>417</fpage>
<lpage>423</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S2221-24342022000400417&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S2221-24342022000400417&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S2221-24342022000400417&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Fundamento: las enfermedades crónicas conforme evolucionan requieren del uso de varios medicamentos para su control. Este uso se incrementa mientras más tiempo tengan desde su diagnóstico, situación que puede repercutir negativamente en la salud de los pacientes por las interacciones medicamentosas.  Objetivo: asociar la polifarmacia con las principales enfermedades crónicas en pacientes atendidos en un hospital provincial peruano.  Métodos:  se realizó un estudio descriptivo, retrospectivo y transversal, ejecutado en setiembre del 2022, con 159 pacientes con diabetes tipo 2 e hipertensión arterial atendidos en el Hospital José Hernán Soto Cadenillas de Chota. Los datos de caracterización, fármacos consumidos y de las enfermedades crónicas se obtuvieron del Sistema de Padrón Nominal de pacientes inscritos en el Hospital. El análisis independiente de variables se hizo mediante frecuencias absolutas y relativas, intervalos de confianza al 95 %, media, desviación estándar, mínimo, máximo y la asociación entre variables con chi cuadrado de independencia, con p &lt; 0,05 de significancia estadística.  Resultados el 72,3 % de pacientes fueron mujeres, su media de edad fue de 68,6 años, el consumo de 4 fármacos fue el promedio para la comorbilidad de diabetes tipo 2 e hipertensión arterial, seguido de 3 fármacos en la hipertensión arterial, lo que representó polifarmacia para ambos casos (30,2 y 23,8 %, respectivamente). Existe asociación estadística significativa entre el padecimiento de enfermedad crónica y la polifarmacia (p = 0,002).  Conclusión: la mayoría de pacientes consumen de 3 a más fármacos, máxime si padecen ambas enfermedades, por lo que la polifarmacia se asocia significativamente a la ocurrencia de enfermedades crónicas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Background: chronic diseases as they evolve require the use of several medications for their control. This use increases the longer they have been since their diagnosis, a situation that can have a negative impact on the health of patients due to drug interactions.  Objective: to associate polypharmacy with the main chronic diseases in patients treated in a Peruvian provincial hospital.  Methods:  a descriptive, retrospective and cross-sectional study was carried out, carried out in September 2022, with 159 patients with type 2 diabetes and arterial hypertension treated at the José Hernán Soto Cadenillas Hospital in Chota. Characterization data, drugs consumed and chronic diseases were obtained from the Nominal Register System of patients enrolled in the Hospital. The independent analysis of variables was done using absolute and relative frequencies, 95 % confidence intervals, mean, standard deviation, minimum, maximum and the association between variables with chi-square of independence, with p &lt; 0.05 of statistical significance.  Results: 72.3 % of patients were women, their mean age was 68.6 years, the consumption of 4 drugs was the average for the comorbidity of type 2 diabetes and arterial hypertension, followed by 3 drugs in arterial hypertension, which represented polypharmacy for both cases (30.2 and 23.8 %, respectively). There is a significant statistical association between suffering from chronic disease and polypharmacy (p = 0.002).  Conclusion: most patients consume 3 or more drugs, especially if they suffer from both diseases, so polypharmacy is significantly associated with the occurrence of chronic diseases.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedades no transmisibles]]></kwd>
<kwd lng="es"><![CDATA[enfermedad crónica]]></kwd>
<kwd lng="es"><![CDATA[diabetes, hipertensión]]></kwd>
<kwd lng="es"><![CDATA[polifarmacia]]></kwd>
<kwd lng="en"><![CDATA[non-communicable diseases]]></kwd>
<kwd lng="en"><![CDATA[chronic disease]]></kwd>
<kwd lng="en"><![CDATA[diabetes, hypertension]]></kwd>
<kwd lng="en"><![CDATA[polypharmacy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rieckert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Trampisch]]></surname>
<given-names><![CDATA[US]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy in older patients with chronic diseases a cross-sectional analysis of factors associated with excessive polypharmacy]]></article-title>
<collab>Klaaßen R.Drewelow E.Esmail A.Johansson T</collab>
<source><![CDATA[BMC Fam Pract]]></source>
<year>2018</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>113</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthias]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Fernando]]></surname>
<given-names><![CDATA[GV]]></given-names>
</name>
<name>
<surname><![CDATA[Somathilake]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Prathapan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors and patterns of polypharmacy in chronic diseases in a middle-income country]]></article-title>
<source><![CDATA[Int J Physiol Pathophysiol Pharmacol]]></source>
<year>2021</year>
<volume>13</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>158-65</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One size fits all How to optimize the prescribing of appropriate polypharmacy in chronic diseases, using a behavioral approach - a United Kingdom perspective]]></article-title>
<source><![CDATA[Expert Rev Clin Pharmacol]]></source>
<year>2022</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>497-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Remelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ceresini]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Trevisan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Noale]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Volpato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and impact of polypharmacy in older patients with type 2 diabetes]]></article-title>
<source><![CDATA[Aging Clin Exp Res]]></source>
<year>2022</year>
<volume>34</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1969-83</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaconu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Cozma]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dobrica]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Gheorghe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jichitu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ionescu]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Polypharmacy in the Management of Arterial Hypertension-Friend or Foe]]></article-title>
<source><![CDATA[Medicina (Kaunas)]]></source>
<year>2021</year>
<volume>57</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1288</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alwhaibi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potentially Inappropriate Medications Use among Older Adults with Comorbid Diabetes and Hypertension in an Ambulatory Care Setting]]></article-title>
<source><![CDATA[J Diabetes Res]]></source>
<year>2022</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1511</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pietraszek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Drózdz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Makuch]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Domanski]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dudzik]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sociodemographic and Health-Related Factors Influencing Drug Intake among the Elderly Population]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2022</year>
<volume>19</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>8766</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adem]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tegegne]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication Appropriateness, Polypharmacy, and Drug-Drug Interactions in Ambulatory Elderly Patients with Cardiovascular Diseases at Tikur Anbessa Specialized Hospital, Ethiopia]]></article-title>
<source><![CDATA[Clin Interv Aging]]></source>
<year>2022</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>509-17</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwak]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chiadika]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Avritscher]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Deshmukh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Healthcare Expenditure Associated With Polypharmacy in Older Adults With Cardiovascular Diseases]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2022</year>
<volume>169</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>156-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paredes]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Los estilos de vida y características sociales de los pacientes con diabetes mellitus tipo 2 Hospital José Hernán Soto Cadenillas Chota -2015]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Perú ]]></publisher-loc>
<publisher-name><![CDATA[Hospital José Soto Cadenillas de Chota]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klinedinst]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Nelson]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Gloeckner]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Malcolm]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Depression and polypharmacy are risk factors for activity limitation in type 2 diabetes]]></article-title>
<source><![CDATA[Chronic Illn]]></source>
<year>2022</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>320-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosli]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Mazapuspavina]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[NE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship of Self Efficacy in Medication Understanding with Quality of Life among Elderly with Type 2 Diabetes Mellitus on Polypharmacy in Malaysia]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2022</year>
<volume>19</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>3031</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mader]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Aberer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Drechsler]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Pöttler]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenegger]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Köle]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication errors in type 2 diabetes from patients&amp;apos; perspective]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2022</year>
<volume>17</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lean]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McCombie]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Xin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Forget polypharmacy for type 2 diabetes Weight management is a better investment]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2022</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>844-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mecca]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Zenoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fried]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary care clinicians&amp;apos; use of deprescribing recommendations A mixed-methods study]]></article-title>
<source><![CDATA[Patient Educ Couns]]></source>
<year>2022</year>
<volume>105</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2715-20</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
